Evidence map›Paper›PMID 21789741›Full record

ArticleStrahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]2011

Erlotinib-induced rash spares previously irradiated skin.

Irene M Lips, Mariska E Y Koster, Ronald H Houwing, Ernest J A Vonk

Abstract readCase Reports
PubMed Publisher
In one paragraph

Article in Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al], 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Trial
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Irene M LipsDepartment of Radiation Oncology, Radiotherapeutisch Instituut Stedendriehoek en Omstreken (RISO), Deventer, The Netherlands.
Mariska E Y Koster
Ronald H Houwing
Ernest J A Vonk

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundErlotinib is an epidermal growth factor receptor inhibitor prescribed to patients with locally advanced or metastasized non-small cell lung carcinoma after failure of at least one earlier chemotherapy treatment. Approximately 75% of the patients treated with erlotinib develop acneiform skin rashes. CASE REPORT: A patient treated with erlotinib 3 months after finishing concomitant treatment with chemotherapy and radiotherapy for non-small cell lung cancer is presented. Unexpectedly, the part of the skin that had been included in his previously radiotherapy field was completely spared from the erlotinib-induced acneiform skin rash.

conclusionThe exact mechanism of erlotinib-induced rash sparing in previously irradiated skin is unclear. The underlying mechanism of this phenomenon needs to be explored further, because the number of patients being treated with a combination of both therapeutic modalities is increasing. The therapeutic effect of erlotinib in the area of the previously irradiated lesion should be assessed.

Indexed as

Carcinoma, Non-Small-Cell LungCombined Modality TherapyDisease ProgressionDose Fractionation, RadiationDrug EruptionsErlotinib HydrochlorideFatal OutcomeHumansImage Processing, Computer-AssistedLung NeoplasmsMaleMiddle AgedNeoplasm Recurrence, LocalNeoplasm StagingPleural NeoplasmsProtein Kinase InhibitorsErlotinib HydrochlorideProtein Kinase InhibitorsQuinazolines

Identifiers

PMID21789741

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.